Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Työhuone: 4124 (B-stairs, 4th floor) ORCID-tunniste: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- Piecing Together a Broken Tumor Suppressor Phosphatase for Cancer TherapyProtein interactome of the Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Th17 cellsUBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent ApoptosisPWP1 Mediates Nutrient-Dependent Growth Control through Nucleolar Regulation of Ribosomal Gene Expression (2020)
- CellSolubiologi
(B1 Vertaisarvioimaton kirjoitus tieteellisessä lehdessä ) - (2020)
- Current Research in Immunology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2020)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2019)
- Cancers
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficitsThioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide (2019)
- Neurobiology of Aging
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2019)
- Cancer ResearchPLoS ONE
(O2 Muu julkaisu ) - Genistein Decreases APP/tau Phosphorylation and Ameliorates A beta Over-production Through Inhibiting CIP2A (2019)
- Current Alzheimer ResearchCancer MedicineFEBS Journal
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2019)
- International Journal of Cancer
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Tutkimus edelläCIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease (2019)
(D1 Artikkeli ammattilehdessä) - (2018)
- Cell Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastomaOncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2018)
- Proceedings of the National Academy of Sciences of the United States of AmericaInternational Journal of Biochemistry and Cell Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2018)
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Phosphatases catching up with the level of knowledge: Finally druggable? (2018)
- International Journal of Biochemistry and Cell Biology
(B1 Vertaisarvioimaton kirjoitus tieteellisessä lehdessä ) - PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells (2018)
- Science Translational Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer (2018)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back (2018)
(B1 Vertaisarvioimaton kirjoitus tieteellisessä lehdessä ) - (2017)
- EMBO Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer DevelopmentCIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection (2017)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2017)
- Developmental Cell
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2016)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



